Trial Profile
Additional Health and Economic Impact of the Bivalent Versus the Quadrivalent HPV Vaccine in Taiwan: Results of a Prevalence-based Model
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
- Indications Cervical cancer; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 24 Oct 2012 New trial record